

Kenneth A Howard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6896609/publications.pdf>

Version: 2024-02-01

90
papers

6,232
citations

87888

38
h-index

69250

77
g-index

90
all docs

90
docs citations

90
times ranked

10234
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the IL-6/γSnail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 214-224.	0.9	26
2	Albumin Biomolecular Drug Designs Stabilized through Improved Thiol Conjugation and a Modular Locked Nucleic Acid Functionalized Assembly. <i>Bioconjugate Chemistry</i> , 2022, 33, 333-342.	3.6	6
3	Functionalized Acyclic (<sc>I</sc>)Threoninol Nucleic Acid Four-Way Junction with High Stability In Vitro and In Vivo. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	13.8	7
4	Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. <i>Communications Biology</i> , 2021, 4, 310.	4.4	29
5	Bioengineered solutions to improve cancer immunotherapies. <i>Therapeutic Delivery</i> , 2021, 12, 339-341.	2.2	1
6	FcRn expression in cancer: Mechanistic basis and therapeutic opportunities. <i>Journal of Controlled Release</i> , 2021, 337, 248-257.	9.9	15
7	Roadmap on nanomedicine. <i>Nanotechnology</i> , 2021, 32, 012001.	2.6	17
8	Albumin-based drug designs for pharmacokinetic modulation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 783-795.	3.3	42
9	FcRn overexpression in human cancer drives albumin recycling and cell growth; a mechanistic basis for exploitation in targeted albumin-drug designs. <i>Journal of Controlled Release</i> , 2020, 322, 53-63.	9.9	29
10	Regulation of Gdf5 expression in joint remodelling, repair and osteoarthritis. <i>Scientific Reports</i> , 2020, 10, 157.	3.3	44
11	Size-Selective Phagocytic Clearance of Fibrillar α -Synuclein through Conformational Activation of Complement Receptor 4. <i>Journal of Immunology</i> , 2020, 204, 1345-1361.	0.8	23
12	Albumin-Binding Fatty Acid-Modified Gapmer Antisense Oligonucleotides for Modulation of Pharmacokinetics. <i>Methods in Molecular Biology</i> , 2020, 2176, 163-174.	0.9	1
13	Optimised approach to albumin-drug conjugates using monobromomaleimide-C-2 linkers. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 7870-7873.	2.8	14
14	A new class of recombinant human albumin with multiple surface thiols exhibits stable conjugation and enhanced FcRn binding and blood circulation. <i>Journal of Biological Chemistry</i> , 2019, 294, 3735-3743.	3.4	15
15	Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine. <i>Clinical Chemistry</i> , 2019, 65, 540-548.	3.2	20
16	Intracellular bacteria engage a STING-TBK1-MVB12b pathway to enable paracrine cGAS-STING signalling. <i>Nature Microbiology</i> , 2019, 4, 701-713.	13.3	100
17	Fibrin-hyaluronic acid hydrogel-based delivery of antisense oligonucleotides for ADAMTS5 inhibition in co-delivered and resident joint cells in osteoarthritis. <i>Journal of Controlled Release</i> , 2019, 294, 247-258.	9.9	34
18	Targeting Biological Barriers: Turning a Wall into a Therapeutic Springboard. <i>Molecular Therapy</i> , 2018, 26, 933-934.	8.2	7

#	ARTICLE	IF	CITATIONS
19	Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement. <i>Journal of Controlled Release</i> , 2018, 287, 132-141.	9.9	29
20	Palmitoylated phosphodiester gapmer designs with albumin binding capacity and maintained <i>in vitro</i> gene silencing activity. <i>Journal of Gene Medicine</i> , 2018, 20, e3025.	2.8	4
21	The random co-polymer glatiramer acetate rapidly kills primary human leukocytes through sialic-acid-dependent cell membrane damage. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2017, 1859, 425-437.	2.6	15
22	Hyaluronic Acid Molecular Weight-Dependent Modulation of Mucin Nanostructure for Potential Mucosal Therapeutic Applications. <i>Molecular Pharmaceutics</i> , 2017, 14, 2359-2367.	4.6	28
23	Site-selective conjugation of an anticoagulant aptamer to recombinant albumins and maintenance of neonatal Fc receptor binding. <i>Nanotechnology</i> , 2017, 28, 204004.	2.6	20
24	A hyaluronic acid-based hydrogel enabling CD44-mediated chondrocyte binding and gapmer oligonucleotide release for modulation of gene expression in osteoarthritis. <i>Journal of Controlled Release</i> , 2017, 253, 153-159.	9.9	47
25	Pellet-free isolation of human and bovine milk extracellular vesicles by size-exclusion chromatography. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1294340.	12.2	101
26	The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria. <i>Scientific Reports</i> , 2017, 7, 15653.	3.3	25
27	An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 9, 284-293.	5.1	23
28	Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation. <i>Molecular Therapy</i> , 2017, 25, 1710-1717.	8.2	39
29	Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin. <i>Journal of Biological Chemistry</i> , 2017, 292, 13312-13322.	3.4	60
30	Albumin-based drug delivery using cysteine 34 chemical conjugates – important considerations and requirements. <i>Therapeutic Delivery</i> , 2017, 8, 511-519.	2.2	20
31	An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing. <i>Journal of Controlled Release</i> , 2016, 232, 143-151.	9.9	31
32	Multimodal Imaging-Guided Antitumor Photothermal Therapy and Drug Delivery Using Bismuth Selenide Spherical Sponge. <i>ACS Nano</i> , 2016, 10, 9646-9658.	14.6	175
33	Human Serum Albumin-Coated Prussian Blue Nanoparticles as pH/Thermotriggred Drug Delivery Vehicles for Cancer Thermochemotherapy. <i>Particle and Particle Systems Characterization</i> , 2016, 33, 53-62.	2.3	42
34	Highly porous PEGylated Bi ₂ S ₃ nano-urchins as a versatile platform for in vivo triple-modal imaging, photothermal therapy and drug delivery. <i>Nanoscale</i> , 2016, 8, 16005-16016.	5.6	90
35	Albumin-based drug delivery: harnessing nature to cure disease. <i>Molecular and Cellular Therapies</i> , 2016, 4, 3.	0.2	480
36	Chip-Free Microscale-Based Synthesis of Chitosan-Based Gene Silencing Nanoparticles. <i>Particle and Particle Systems Characterization</i> , 2016, 33, 279-285.	2.3	1

#	ARTICLE	IF	CITATIONS
37	Nanomedicine: Working Towards Defining the Field. <i>Advances in Delivery Science and Technology</i> , 2016, , 1-12.	0.4	5
38	Neonatal Fc Receptor Binding Tolerance toward the Covalent Conjugation of Payloads to Cysteine 34 of Human Albumin Variants. <i>Molecular Pharmaceutics</i> , 2016, 13, 677-682.	4.6	18
39	Multifunctional Bismuth Selenide Nanocomposites for Antitumor Thermo-Chemotherapy and Imaging. <i>ACS Nano</i> , 2016, 10, 984-997.	14.6	234
40	Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. <i>Journal of Controlled Release</i> , 2016, 223, 22-30.	9.9	35
41	Mucin-mediated nanocarrier disassembly for triggered uptake of oligonucleotides as a delivery strategy for the potential treatment of mucosal tumours. <i>Nanoscale</i> , 2016, 8, 12599-12607.	5.6	10
42	Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 29685.	12.2	86
43	Tunable CD44-Specific Cellular Retargeting with Hyaluronic Acid Nanoshells. <i>Pharmaceutical Research</i> , 2015, 32, 1462-1474.	3.5	18
44	Albumin: the next-generation delivery technology. <i>Therapeutic Delivery</i> , 2015, 6, 265-268.	2.2	19
45	Chitosan-Based Nanoparticles for Mucosal Delivery of RNAi Therapeutics. <i>Advances in Genetics</i> , 2014, 88, 325-352.	1.8	26
46	Extended blood circulation and joint accumulation of a p(HPMA-co-AzMA)-based nanoconjugate in a murine model of rheumatoid arthritis. <i>Molecular and Cellular Therapies</i> , 2014, 2, 29.	0.2	5
47	The application of RNAi-based treatments for inflammatory bowel disease. <i>Drug Delivery and Translational Research</i> , 2014, 4, 4-18.	5.8	12
48	RNA interference-based therapeutics and diagnostics. <i>Drug Delivery and Translational Research</i> , 2014, 4, 1-2.	5.8	2
49	Cell type and transfection reagent-dependent effects on viability, cell content, cell cycle and inflammation of RNAi in human primary mesenchymal cells. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 53, 35-44.	4.0	19
50	Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors. <i>Proteomics</i> , 2014, 14, 699-712.	2.2	148
51	Polycation-based nanoparticles for RNAi-mediated cancer treatment. <i>Cancer Letters</i> , 2014, 352, 66-80.	7.2	22
52	Ultraporous interweaving electrospun microfibers from PCL/PEO binary blends and their inflammatory responses. <i>Nanoscale</i> , 2014, 6, 3392.	5.6	45
53	Mucus barrier-triggered disassembly of siRNA nanocarriers. <i>Nanoscale</i> , 2014, 6, 12547-12554.	5.6	11
54	Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties. <i>Cancer Research</i> , 2014, 74, 5758-5771.	0.9	237

#	ARTICLE	IF	CITATIONS
55	Spatial Mapping and Quantification of Soft and Hard Protein Coronas at Silver Nanocubes. <i>Nano Letters</i> , 2014, 14, 2086-2093.	9.1	85
56	Comparative analysis of discrete exosome fractions obtained by differential centrifugation. <i>Journal of Extracellular Vesicles</i> , 2014, 3, 25011.	12.2	262
57	Providing the full picture: a mandate for standardizing nanoparticle-based drug delivery. <i>Nanomedicine</i> , 2013, 8, 1031-1033.	3.3	10
58	Surface Analysis of PEGylated Nano-Shields on Nanoparticles Installed by Hydrophobic Anchors. <i>Pharmaceutical Research</i> , 2013, 30, 1758-1767.	3.5	10
59	Mucosal Delivery of RNAi Therapeutics. <i>Advances in Delivery Science and Technology</i> , 2013, , 97-125.	0.4	2
60	Clinical translation of RNAi-based treatments for respiratory diseases. <i>Drug Delivery and Translational Research</i> , 2013, 3, 84-99.	5.8	6
61	Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e76.	5.1	65
62	Synthesis of click-reactive HPMA copolymers using RAFT polymerization for drug delivery applications. <i>Journal of Polymer Science Part A</i> , 2013, 51, 5091-5099.	2.3	31
63	Peritoneal macrophages mediated delivery of chitosan/siRNA nanoparticle to the lesion site in a murine radiation-induced fibrosis model. <i>Acta Oncologica</i> , 2013, 52, 1730-1738.	1.8	22
64	Oligonucleotide Delivery to the Lung: Waiting to Inhale. <i>Molecular Therapy - Nucleic Acids</i> , 2012, 1, e1.	5.1	11
65	Polycation-based nanoparticle delivery of RNAi therapeutics: Adverse effects and solutions. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1717-1729.	13.7	136
66	Accumulation of magnetic iron oxide nanoparticles coated with variably sized polyethylene glycol in murine tumors. <i>Nanoscale</i> , 2012, 4, 2352.	5.6	61
67	Antimicrobial Effect of Chitosan Nanoparticles on <i>Streptococcus mutans</i> Biofilms. <i>Applied and Environmental Microbiology</i> , 2011, 77, 3892-3895.	3.1	183
68	Surface functionalisation of PLGA nanoparticles for gene silencing. <i>Biomaterials</i> , 2010, 31, 5671-5677.	11.4	53
69	Pulmonary Gene Silencing in Transgenic EGFP Mice Using Aerosolised Chitosan/siRNA Nanoparticles. <i>Pharmaceutical Research</i> , 2010, 27, 2520-2527.	3.5	87
70	Chitosan/siRNA Nanoparticles Biofunctionalize Nerve Implants and Enable Neurite Outgrowth. <i>Nano Letters</i> , 2010, 10, 3933-3939.	9.1	78
71	siRNA Nanoparticle Functionalization of Nanostructured Scaffolds Enables Controlled Multilineage Differentiation of Stem Cells. <i>Molecular Therapy</i> , 2010, 18, 2018-2027.	8.2	81
72	Bioresponsive hyperbranched polymers for siRNA and miRNA delivery. <i>Journal of Drug Targeting</i> , 2010, 18, 812-820.	4.4	43

#	ARTICLE	IF	CITATIONS
73	Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNF $\hat{\pm}$ prevents radiation-induced fibrosis. <i>Radiotherapy and Oncology</i> , 2010, 97, 143-148.	0.6	57
74	Size-Dependent Accumulation of PEGylated Silane-Coated Magnetic Iron Oxide Nanoparticles in Murine Tumors. <i>ACS Nano</i> , 2009, 3, 1947-1951.	14.6	242
75	Chitosan/siRNA Nanoparticle-mediated TNF $\hat{\pm}$ Knockdown in Peritoneal Macrophages for Anti-inflammatory Treatment in a Murine Arthritis Model. <i>Molecular Therapy</i> , 2009, 17, 162-168.	8.2	270
76	Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides. <i>Journal of Gene Medicine</i> , 2008, 10, 81-93.	2.8	43
77	Delivery of siRNA from lyophilized polymeric surfaces. <i>Biomaterials</i> , 2008, 29, 506-512.	11.4	100
78	Visualization of thermally activated nanocarriers using in situ atomic force microscopy. <i>Nanotechnology</i> , 2007, 18, 185501.	2.6	3
79	Direct Force Measurements between siRNA and Chitosan Molecules Using Force Spectroscopy. <i>Biophysical Journal</i> , 2007, 93, 952-959.	0.5	52
80	Polycation-based nanoparticle delivery for improved RNA interference therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1811-1822.	3.1	44
81	The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. <i>Biomaterials</i> , 2007, 28, 1280-1288.	11.4	382
82	Nanocarrier Stimuli-Activated Gene Delivery. <i>Small</i> , 2007, 3, 54-57.	10.0	48
83	RNA Interference in Vitro and in Vivo Using a Novel Chitosan/siRNA Nanoparticle System. <i>Molecular Therapy</i> , 2006, 14, 476-484.	8.2	549
84	Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine. <i>Vaccine</i> , 2006, 24, 4433-4439.	3.8	33
85	Formulation of a microparticle carrier for oral polyplex-based DNA vaccines. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 149-157.	9.0	15
86	Importance of Lateral and Steric Stabilization of Polyelectrolyte Gene Delivery Vectors for Extended Systemic Circulation. <i>Molecular Therapy</i> , 2002, 5, 463-472.	8.2	273
87	Physicochemical and biological characterisation of an antisense oligonucleotide targeted against the bcl-2 mRNA complexed with cationic hydrophilic copolymers. <i>European Journal of Pharmaceutical Sciences</i> , 2000, 10, 169-177.	4.0	26
88	Decreased Binding to Proteins and Cells of Polymeric Gene Delivery Vectors Surface Modified with a Multivalent Hydrophilic Polymer and Retargeting through Attachment of Transferrin. <i>Journal of Biological Chemistry</i> , 2000, 275, 3793-3802.	3.4	148
89	Steric Stabilization of poly-L-Lysine/DNA Complexes by the Covalent Attachment of Semitelechelic poly[N-(2-Hydroxypropyl)methacrylamide]. <i>Bioconjugate Chemistry</i> , 2000, 11, 492-501.	3.6	109
90	Functionalized Acyclic (L)-Threoninol Nucleic Acid Four Way Junction with High Stability in Vitro and in Vivo. <i>Angewandte Chemie</i> , 0, , .	2.0	0